Introgen Therapeutics, Inc.
(NASDAQ:INGN)|
0.11 -0.13 (-54.17%) Dec 04 - Close |
|
|
|
After-Hours 0.11 0.00 (0.00%) Thu, 4 Dec 2008 7:40 PM
- Compare INGN with:
- View: Line | Candlestick
Company Profile
Introgen Therapeutics, Inc.
301 Congress Avenue
Austin, TX 78701
United States - Map
Phone: (512) 708-9310
Fax: (512) 708-9311
Website: www.introgen.com
CEO: David G. Nance
Employees: 80
Sector: Healthcare
Industry Group: Drugs
Industry: Biotechnology
Developer of anti-cancer gene therapies
A biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases.
Recent news for INGN
-
Introgen files for bankruptcy, sees exit in 2009
Reuters - Yesterday at 6:26 ET
-
Introgen Files Voluntary Chapter 11 Petition to Facilitate Restructuring
Business Wire - Yesterday at 4:30 ET
-
INTROGEN THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online - Nov 26 at 5:15 ET
-
Introgen Restructures Operations to Focus on Revenue-Generating Manufacturing Capabilities
Business Wire - Nov 26 at 4:30 ET
-
INTROGEN THERAPEUTICS INC Financials
EDGAR Online Financials - Nov 21 at 9:04 ET
-
INTROGEN THERAPEUTICS INC Financials
EDGAR Online Financials - Nov 19 at 9:04 ET
-
Business Wire - Nov 18 at 6:18 ET
-
EDGAR Online - Nov 18 at 5:30 ET
-
New Star Analyst Rankings for Introgen Therapeutics, Inc.
StarMine - Nov 12 at 9:24 ET
-
INTROGEN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online - Nov 12 at 6:17 ET